Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

Scientists in southern China have developed a new strategy to fight cancer by forcing tumor cells to "expose themselves" to ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...

The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...